Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOUND-MCL: acalabrutinib plus R-CHOP for previously untreated mantle cell lymphoma
2025-521152-34-00Phase 2Authorised
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of acalabrutinib in mantle cell lymphoma (MCL), sponsored by AstraZeneca. Primary endpoint: Investigator-assessed best overall response rate. Planned start Sep 2025; status: authorised.
02
Drugs
acalabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2025-521152-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521152-34-00.